You are here

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Last updated on April 8, 2019

FOR MORE INFORMATION
Study Location
University of Alabama at Birmingham
Birmingham, Alabama, 35233 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
ALK-positive Advanced NSCLC
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically or cytologically proved diagnosis of locally advanced recurrent or
metastatic non-squamous NSCLC that is not suitable for local curative treatment.

- Alk-positive NSCLC as determined by a test that is approved or validated for use as a
companion diagnostic test.

- No prior systemic therapy for metastatic disease.

- Adjuvant chemotherapy more than 12 months prior to study enrollment.

- Measurable disease as per RECIST 1.1

- ECOG PS 0 or 1.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior exposure to ALK receptor tyrosine kinase inhibitor, anti-PD1, anti-PDL1 or any
drug targeting T-cell checkpoint pathways.

- known diagnosis of immunodeficiency or is receiving systemic steroid therapy or other
form of immunosuppressive therapy within 7 days of clinical trial treatment.

- Active autoimmune disease that has required systemic treatment in the past 3 months.

- History of extensive disseminated interstitial fibrosis or any grade of interstitial
lung disease.

NCT02511184
Pfizer
Terminated
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now